Results 121 to 130 of about 1,369,571 (283)

A Delphi consensus project to capture experts' opinion on hyperkalaemia management across the cardiorenal spectrum

ESC Heart Failure, Volume 12, Issue 2, Page 1132-1140, April 2025.
Abstract The main purpose of this project was to capture experts' opinion on hyperkalaemia management and form best practice recommendations for cardiorenal patients in Greece. A steering committee of nephrologists and cardiologists developed 37 statements. An online questionnaire completed by 32 experts in cardiorenal management in Greece.
Christina Chrysohoou, Maria Marketou, Maria Aktsiali, Ioannis Griveas   +3 more
wiley   +1 more source

Myosin Light Chain Phosphatase Plays an Important Role in Cardiac Fibrosis in a Model of Mineralocorticoid Receptor‐Associated Hypertension

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Myosin phosphatase targeting subunit 2 (MYPT2) is an important subunit of cardiac MLC (myosin light chain) phosphatase, which plays a crucial role in regulating the phosphorylation of MLC to phospho‐MLC (p‐MLC).
Zhe Ye, Ryuji Okamoto, Hiromasa Ito, Rie Ito, Keishi Moriwaki, Mizuki Ichikawa, Lupiya Kimena, Yusuf Ali, Masaaki Ito, Celso E. Gomez‐Sanchez, Kaoru Dohi   +10 more
doaj   +1 more source

FDG PET/CT imaging and circulating biomarkers of inflammation in desmoplakin cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1485-1489, April 2025.
Abstract Aims Inflammation has been implicated in the pathogenesis of desmoplakin (DSP) cardiomyopathy, and retrospective studies have described abnormal myocardial fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in symptomatic patients eventually diagnosed with DSP cardiomyopathy.
Sanjay Divakaran, Vinay Randhawa, Usman A. Tahir, Matthew Robertson, Anam A. Waheed, Anna Perillo, Leanne Barrett, Ron Blankstein, Mark W. Feinberg, Marcelo F. Di Carli, Neal K. Lakdawala   +10 more
wiley   +1 more source

Distribution and regulation of renal mineralocorticoid and glucocorticoid receptor mRNA.

, 1992
Adrenal corticosteroid hormones play an important role in the maintenance of body fluid and electrolyte balance. In spite of their physiological significance, the specific target sites for adrenal corticosteroid action in the kidney, as well as the ...
Todd-Turla, Karyn Marie
core   +4 more sources

Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction in Preclinical Nondiabetic Chronic Kidney Disease

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The mineralocorticoid receptor plays a significant role in the development of chronic kidney disease (CKD) and associated cardiovascular complications.
Ixchel Lima Posada, Matthieu Soulié, Yohan Stephan, Roberto Palacios Ramirez, Benjamin Bonnard, Lionel Nicol, Bertram Pitt, Peter Kolkhof, Paul Mulder, Frederic Jaisser   +9 more
doaj   +1 more source

Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review

Efficacy and Safety of Mineralocorticoid Receptor Antagonists in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic ...
Lídia Ana Zytinsky Moura, Ricardo Mourilhe Rocha, Diretrizes SBC, Silvia Marinho Martins, Denilson Campos de Albuquerque, Marcus Vinicius Simões, Fabiana G. Marcondes Braga, Luis Claudio Danzmann, Mucio Tavares de Oliveira-Júnior, José Albuquerque de Figueiredo-Neto   +9 more
core   +2 more sources

Cyproheptadine and mineralocorticoid effector mechanisms.

, 1983
Cyproheptadine has recently been reported to blunt the furosemide-induced rise in PRA in normal subjects and to acutely lower plasma aldosterone levels in patients with hyperaldosteronism due to bilateral adrenal hyperplasia; both actions have ...
ARMANINI, DECIO, GOLAND GJ, ADAM WR, FUNDER J.W., DECIO ARMANINI, JOHN W. FUNDER, GARY J. GOLAND, WILLIAM R. ADAM   +7 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Clinical application of mineralocorticoid receptor antagonists in chronic heart failure

, 2014
The review of literature discusses pathogenetic aspects of chronic heart failure and post-infarction remodelling in the heart. The focus is on the role of neurohormonal activation and the important role of aldosterone.
MG Bubnova
core   +1 more source

Mineralocorticoid Receptors ☆ [PDF]

Pediatric Research, 1993
openaire   +1 more source